Advances in Classification and Treatment of Non-Hodgkin Lymphoma Mantle Cell

被引:1
|
作者
Rule, Simon [1 ]
Johns, Sophie [2 ]
机构
[1] Plymouth Univ, Med Sch, Plymouth Sci Pk,Res Way, Plymouth PL6 8BT, Devon, England
[2] Univ Hosp Plymouth, Plymouth, Devon, England
来源
CANCER JOURNAL | 2020年 / 26卷 / 04期
关键词
BTK inhibitors; chemotherapy-free regimens; mantle cell lymphoma; OPEN-LABEL; PHASE-II; MOLECULAR PATHOGENESIS; DOSE CYTARABINE; SINGLE-ARM; RITUXIMAB; IBRUTINIB; TRANSPLANTATION; MCL; MULTICENTER;
D O I
10.1097/PPO.0000000000000462
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mantle cell lymphoma is a rare, aggressive, and largely incurable form of non-Hodgkin lymphoma. There are a number of well-characterized prognostic features but nothing that can help guide therapy. Treatment with chemotherapy is generally effective in the short term, but relapse is inevitable and subsequent treatment is challenging. The use of Bruton tyrosine kinase inhibitors, however, has transformed practice. These agents are highly active in relapsed disease and are very well-tolerated drugs. Chemotherapy-free combinations using Bruton tyrosine kinase inhibitors look very exciting and will likely evolve to be part of frontline care in the future.
引用
收藏
页码:348 / 356
页数:9
相关论文
共 50 条
  • [1] MANTLE CELL LYMPHOMA, AN UNCOMMON PRESENTATION OF NON-HODGKIN LYMPHOMA
    Fadeyi, Olaniyi
    Gupta, Lakshita
    Anugu, Gautam
    Hakim, Asaad
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (07) : 1614 - 1615
  • [2] Advances in the treatment of non-Hodgkin's lymphoma
    Cerny, T
    Gillessen, S
    [J]. ANNALS OF ONCOLOGY, 2002, 13 : 211 - 216
  • [3] Advances in treatment for non-Hodgkin"s lymphoma
    Gerrard, MP
    [J]. CANCER AND THE ADOLESCENT, SECOND EDITION, 2005, : 72 - 82
  • [4] Current therapeutic advances in the treatment of non-Hodgkin lymphoma
    Hernandez-Rivera, Gabriela
    Aguayo-Gonzalez, Alvaro
    Cano-Castellanos, Raul
    Martin Loarca-Pina, Luis
    [J]. GACETA MEDICA DE MEXICO, 2008, 144 (03): : 275 - 277
  • [5] Immunotherapy in non-Hodgkin's lymphoma: Treatment advances
    Fisher, RI
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (02) : 1 - 2
  • [6] Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?
    Bertrand Coiffier
    [J]. Nature Clinical Practice Oncology, 2005, 2 : 388 - 389
  • [7] Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?
    Coiffier, B
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (08): : 388 - 389
  • [8] Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes
    Smedby, Karin E.
    Hjalgrim, Henrik
    [J]. SEMINARS IN CANCER BIOLOGY, 2011, 21 (05) : 293 - 298
  • [9] New advances in the treatment of non-Hodgkin lymphoma with monoclonal antibodies
    Buske, C
    Feuring-Buske, M
    Unterhalt, M
    Hiddemann, W
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 124 (27) : 842 - 847
  • [10] Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma
    Liu, Shuxian
    Xu, Minghao
    Zhong, Lei
    Tong, Xiangmin
    Qian, Suying
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (09) : 895 - 907